Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Stress Echo 2030 Study: A Flagship Project of the Italian Society of Echocardiography and Cardiovascular Imaging
Picano, Eugenio, Padang, Ratnasari , Kane, Garvan C. , Villarraga, Hector R. , Arruda‐Olson, Adelaide M. , Vazquez, Jesus Peteiro , Boshchenko, A , Журавлева, О. А. , Sviazova, Natalia , Balkevičienė, Laura, Djordjevic‐Dikic, Ana , Kobal, Sergio , Lisi, Matteo , Merli, Elisa , Manganelli, F, Daros, Clarissa Borguezan , D’Alfonso, Maria Grazia , Mori, Fabio , Kasprzak, Jarosław D. , Safarova, Ayten, Timofeeva, T. N. , Mosto, Hugo , Wierzbowska‐Drabik, Karina , Ratanasit, Nithima , Colonna, Paolo , Ostojić, Miodrag , Cortigiani, Lauro , Rigo, Fausto , Benfari, Giovanni , Soulis, Dimitrios , Yin, Lixue , Mazzi, Alberto, Haber, Diego M. Lowenstein, Marconi, Sofia, Tripepi, Giovanni Luigi, Nes, Michele De, Bartolacelli, Ylenia , Villari, Bruno, Wierzbowska-Drabik, Karina , Kasprzak, Jaroslaw D , Benfari, Giovanni , Colonna, Paolo , Boshchenko, Alla , Ciampi, Quirino , Arbucci, Rosina , Zagatina, A , Kalinina, Elena , Ryabova, Tamara , Čelutkienė, Jelena , Saad, Ariel K. , Bursi, Francesca , Rodríguez‐Zanella, Hugo , Gaibazzi, Nicola , Costantino, Marco Fabio , Kovačević-Preradović, Tamara , Varga, Albert , Nikolic, Aleksandra, Cocchia, Rosangela , Pálinkás, Attila , Pálinkás, Eszter Dalma , Valente, Filipa Xavier , Wang, Yi , Heyning, Caroline M. Van De , Mazzi, Alberto, Lowenstein, Jorge , Barbieri, Andréa , Mantovani, Francesca , Pepi, Mauro , Carerj, Scipione , Pellikka, Patricia A.

Mayo Clinic

Journal of Cardiovascular Echography | May 1, 2025 | Volume: 35 | Issue: 1 | Pages: 1-7

10.4103/jcecho.jcecho_2_25 | PMID 40463758 Get It

Over the past decade, stress echocardiography has evolved from a test for assessing epicardial artery stenosis to a comprehensive functional test, targeting multiple cardiovascular parameters. The new approach includes several structured steps: (a) evaluating regional wall motion abnormalities to detect epicardial artery stenosis or vasospasm; (b) assessing pulmonary congestion and diastolic function via B-lines with lung ultrasound; (c) gauging preload and contractile reserve with volumetric echocardiography; (d) measuring coronary microvascular reserve using Doppler-based coronary flow velocity in the middistal left anterior descending artery; and (e) determining cardiac sympathetic reserve by tracking heart rate reserve on an ECG. This evolution was supported extensively by the Italian Society of Echocardiography and Cardiovascular Imaging (SIECVI), which played a key role in five areas: (1) developing the initial, curiosity-driven project; (2) disseminating protocols and results at national and international conferences, supporting logistic infrastructure and publication expenses; (3) establishing a digital platform (customized Redcap) for data entry and storage; (4) facilitating patient recruitment across 19 Italian centers; and (5) offering formal endorsement through six presidencies, adding credibility and reach beyond any single institution. The protocol quickly advanced from concept to high-impact publications, earning inclusion in 2024 specialty guidelines. Initially Italian-led, the study now includes 50 centers across 20 countries (e.g. USA and China). Beyond the 50 peer-reviewed papers published in 2016–2024, this study offers a novel, sustainable approach to cardiac stress testing, providing more information at lower costs, with zero radiation and minimal environmental impact. SIECVI’s endorsement was instrumental in amplifying the study’s rigor and outreach.
UNISOM: Unified Somatic Calling and Machine Learning-based Classification Enhance the Discovery of CHIP
Tian, Shulan , Jenkinson, Garrett , Ferrer, Alejandro Tiana, Yan, Huihuang , Morales‐Rosado, Joel A. , Wang, Kevin L. , Lasho, Terra L. , Yan, Benjamin B. , Baheti, Saurabh , Olson, Janet E. , Patnaik, Mrinal M. , Klee, Eric W. , Ferrer, Alejandro , Ferrer, Alejandro , Baughn, Linda B , Ding, Wei , Slager, Susan L , Patnaik, Mrinal , Lazaridis, Konstantinos N , Klee, Eric W , Olson, Janet E , Lasho, Terra L , Tian, Shulan , Morales-Rosado, Joel A , Baughn, Linda B. , Slager, Susan L. , Lazaridis, Konstantinos N.

Mayo Clinic

Genomics, Proteomics & Bioinformatics | April 29, 2025 | Volume: 23 | Issue: 2 | Pages: No page available

10.1093/gpbjnl/qzaf040 | PMID 40300108 Get It

Abstract Clonal hematopoiesis (CH) of indeterminate potential (CHIP), driven by somatic mutations in leukemia-associated genes, confers increased risk of hematologic malignancies, cardiovascular disease, and all-cause mortality. In blood of healthy individuals, small CH clones can expand over time to reach 2% variant allele frequency (VAF), the current threshold for CHIP. Nevertheless, reliable detection of low-VAF CHIP mutations is challenging, often relying on deep targeted sequencing. Here, we present UNISOM, a streamlined workflow for enhancing CHIP detection from whole-genome and whole-exome sequencing data that are underpowered, especially for low VAFs. UNISOM utilizes a meta-caller for variant detection, in couple with machine learning models which classify variants into CHIP, germline, and artifact. In whole-exome sequencing data, UNISOM recovered nearly 80% of the CHIP mutations identified via deep targeted sequencing in the same cohort. Applied to whole-genome sequencing data from Mayo Clinic Biobank, it recapitulated the patterns previously established in much larger cohorts, including the most frequently mutated CHIP genes and predominant mutation types and signatures, as well as strong associations of CHIP with age and smoking status. Notably, 30% of the identified CHIP mutations had < 5% VAFs, demonstrating its high sensitivity toward small mutant clones. This workflow is applicable to CHIP screening in population genomic studies. The UNISOM pipeline is freely available at https://github.com/shulanmayo/UNISOM and https://ngdc.cncb.ac.cn/biocode/tool/7816.
Clinical characteristics and outcomes of primary orbital lymphoma
Wang, Kenny Y. , Kim, B. Michelle, Yu, Caroline , Welk, Grant M. , Churchill, Robert , White, Launia J. , Hodge, David O. , Dalvin, Lauren A. , Tooley, Andrea A. , Yu, Caroline Y, Churchill, Robert A , Dalvin, Lauren A

Mayo Clinic

European Journal of Ophthalmology | April 29, 2025 | Volume: 35 | Issue: 5 | Pages: 1776-1785

10.1177/11206721251338705 | PMID 40296647 Get It

Purpose To describe the clinical characteristics, histopathologic subtype distribution, treatment, and outcomes of patients with primary orbital lymphoma. Major Findings There were 126 biopsy-confirmed cases of primary orbital lymphoma, with 81 (64.3%) female and 110 (87.3%) white. The average age at diagnosis was 62.7 ± 13.9 years. There were 26 (20.6%) cases with bilateral involvement. The most frequent lymphoma subtype was MALT lymphoma (N = 76, 60.3%), followed by diffuse large B-cell lymphoma (N = 18, 14.3%) and follicular lymphoma (N = 12, 9.5%). Prognosis was generally favorable, as local recurrence occurred in only 14 (11.1%) patients and final best corrected visual acuity (BCVA) loss of >1 line was seen in 30 (28.0%) patients. Bilateral lymphoma and advanced stage (Ann Arbor Stage III or IV) at presentation were associated with increased risk of local recurrence ( p = 0.0025, p = 0.049). Improved disease-specific survival was associated with diagnosis at Stage I or II ( p = 0.013), MALT subtype ( p = 0.034), or lack of chemotherapy requirement as primary treatment ( p = 0.0073). Conclusions In this single center academic cohort, MALT lymphoma subtype was most common. Overall orbital recurrence frequency was low, and bilateral lymphoma and advanced stage were associated with increased risk of local recurrence. MALT lymphoma subtype was associated with improved disease-specific survival. Long-term follow-up showed that most patients retained good visual acuity in the affected eye(s).
Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib study
Ahmed, Kamran A. , Kim, Younchul, Kim, Sungjune, DeJesus, Michelle, Arrington, John A., Armaghani, Avan , Costa, Ricardo , Loftus, Loretta , Rosa, Marilin , Díaz, Roberto , Tran, Nam , Czerniecki, Brian J. , Yu, Hsiang-Hsuan Michael, Czerniecki, Brian J , Wang, Min , Soyano, Aixa , Caudell, Jimmy J , Etame, Arnold B. , Soliman, Hatem Hussein , Forsyth, Peter A , Han, Hyo S

Mayo Clinic

Journal for ImmunoTherapy of Cancer | April 28, 2025 | Volume: 13 | Issue: 4 | Pages: e011432

10.1136/jitc-2024-011432 | PMID 40295143 Get It

Background We hypothesized treatment with nivolumab and stereotactic radiosurgery (SRS) would be feasible, well tolerated, and may improve intracranial tumor control over SRS alone for breast cancer brain metastases (BCBM). Methods The study is a phase Ib trial of nivolumab and SRS for BCBM. Clinical trial information: NCT03807765 . Key eligibility criteria include BCBM of all subtypes, age ≥18, Eastern Cooperative Oncology Group Performace Status (ECOG-PS)≤2 with ≤10 brain metastases. Treatment was initiated with a dose of nivolumab (480 mg intravenously) that was repeated every 4 weeks. The initial dose of nivolumab was followed 1 week later by SRS. Blood was collected at baseline and every 4 weeks for flow cytometry and cell-free DNA (cfDNA) assessment. Results A total of 12 patients received SRS to 17 brain metastases. Breast cancer subtypes included triple negative (50%), hormone receptor (HR)+/HER2− (33%), and HR−/HER2+ (17%). Median follow-up from start of protocol therapy is 56 months. No cases of radionecrosis were noted. Two lesions were noted to undergo local failure, both pathologically confirmed, for a 12-month local control of 94%. Median distant intracranial control was 7.4 months with a 12-month control rate of 33%. Median systemic progression-free survival was 7.7 months with a 12-month rate of 42%. Median overall survival (OS) was 24.7 months with a 12-month OS of 75%. Most patients were noted to have an increase in cfDNA throughout study treatment, at week 5 compared with baseline (83%), week 25 compared with baseline (89%), and 100% at first follow-up. Intracranial control was associated with lower levels of CD4 regulatory T cells (Treg) (p=0.03) and higher levels of CD4 T effector memory (p=0.04). Conclusions Nivolumab and SRS is a safe and feasible treatment option in BCBM. Long-term follow-up revealed no cases of radiation necrosis. Trial registration number NCT03807765 .
Global burden of metabolic-associated fatty liver disease: A systematic analysis of Global Burden of Disease Study 2021
Huang, Xiaoquan , Ye, Sitao, Cheryala, Mahesh, Chen, Shiyao , Wang, Yichen , Tian, Li , Huang, Yu-Ting

Mayo Clinic

Chinese Medical Journal | April 25, 2025 | Volume: 138 | Issue: 22 | Pages: 2947-2954

10.1097/cm9.0000000000003517 | PMID 40280878 Get It

Abstract Background: Metabolic-associated fatty liver disease (MAFLD) is a common liver disease and may become the leading cause of severe liver disease in the future. The Global Burden of Disease (GBD) study assesses MAFLD’s impact in countries and regions worldwide, providing insights into its prevalence. Methods: Prevalence data for MAFLD from 1990 to 2021 by country and region in all sex and age groups were collected from the Global Health Data Exchange. The categorization of countries and geographic areas by development was performed using the Sociodemographic Index (SDI). Results: Between 1990 and 2021, the global crude prevalence rate of MAFLD increased from 10.6% to 16.1% (beta-coefficient: 0.2%, 95% confidence interval [CI]: 0.2–0.2%, P <0.001), and the age-standardized prevalence rate was increased from 12.1% to 15.0% (beta-coefficient: 0.1%, 95% CI: 0.1–0.1%, P <0.001). In 2021, MAFLD was estimated to have affected 1.3 billion people worldwide. Significant uptrends were observed in all regions, super regions, and SDI categories. The fastest increase from 1990 to 2021 and the highest prevalence rate in 2021 were experienced by countries and territories with high–middle and middle SDI. An increase in the prevalence of MAFLD from 1990 to 2021 was demonstrated in all but six countries. Conclusions: In 2021, the number of patients affected by MAFLD was doubled compared to 1990, and the prevalence rate increased by over 50%. The burden of MAFLD, as measured by prevalence, was more prominent in countries and territories with middle SDI and in those located in North African and Middle Eastern, possibly due to changes in lifestyle in these areas over the past 30 years.
Activity of contezolid against methicillin-resistant Staphylococcus aureus in a rat model of foreign body osteomyelitis
Herren, Sebastian , Karau, Melissa J. , Koscianski, Christina, Greenwood‐Quaintance, Kerryl E. , Mandrekar, Jayawant N. , Patel, Robin , Herren, Sebastian C , Patel, Robin , Wang, Wen

Mayo Clinic

Microbiology Spectrum | April 25, 2025 | Volume: 13 | Issue: 6 | Pages: No page available

10.1128/spectrum.02372-24 | PMID 40277362 Get It

ABSTRACT Contezolid has activity against methicillin-resistant Staphylococcus aureus (MRSA), a common cause of orthopedic infection. In a rat model of foreign body osteomyelitis, 1.3 log 10 cfu/g bone and 0.5 log 10 cfu/k-wire reduction in MRSA was found in tibiae ( P = 0.0186) and K-wires, respectively, of contezolid-treated compared to untreated rats. No MRSA was recovered from animals receiving rifampin alone or in combination with contezolid or vancomycin. There was no emergence of resistance to contezolid, vancomycin, or rifampin.
Evidence-based guidelines for the pharmacological treatment of migraine, summary version
Ornello, Raffaele , Caponnetto, Valeria , Ahmed, Fayyaz , Al‐Khazali, Haidar M. , Ashina, Sait , Baraldi, Carlo , Bellotti, Alessia, Cevoli, Sabina , Cheng, Shuli, Chiarugi, Alberto , Christensen, Rune Häckert , Chu, Min Kyung , Crema, Santiago , Stefano, Vincenzo Di , Ekizoğlu, Esme , Fallacara, Adriana , Favoni, Valentina , Garces, Kimberly, Granato, Antonio, Granella, Franco, Ha, Woo‐Seok , Hirata, Koichi , Hoffmann, Jan , Hüssler, Eva-Maria, Hussein, Mona , Jenkins, Bronwyn , Labastida‐Ramírez, Alejandro , Laporta, Anna, Levin, Morris , Lupica, Antonino , Mampreso, Edoardo, Martinelli, Daniele , Orologio, Ilaria, Panneerchelvam, Lavindren Luke, Quattrocchi, Silvia, Romanenko, V.I. , Romozzi, Marina , Russo, Antonio , Sances, Grazia , Sarchielli, Paola , Silvestro, Marcello , Tassorelli, Cristina , Tessitore, Alessandro , Christensen, Rune H. , Ambrosini, Anna , Ashina, Sait , Baraldi, Carlo , Bellotti, Alessia , Casillo, Francesco , Cevoli, Sabina , Chiang, Chia-Chun , Chu, Min Kyung , Coppola, Gianluca , Corbelli, Ilenia , De Icco, Roberto , de Tommaso, Marina , Di Stefano, Vincenzo , Diener, Hans-Christoph , Ekizoglu, Esme , Fallacara, Adriana , Favoni, Valentina , Ha, Woo-Seok , Hassan, Amr , Hoffmann, Jan , Hussein, Mona , Iannone, Luigi Francesco , Martinelli, Daniele , Monteith, Teshamae S , Pan, Li-Ling Hope , Rozen, Todd D. , Souza, Marcio Nattan P , Pozo-Rosich, Patricia , Rainero, Innocenzo , Romanenko, Volodymyr , Romozzi, Marina , Russo, Antonio , Sances, Grazia , Schwedt, Todd J , Swerts, Diego Belandrino , Tassorelli, Cristina , Togha, Mansoureh , Vaghi, Gloria , Wang, Shuu-Jiun , Ashina, Messoud , Sacco, Simona , Ornello, Raffaele , Al-Khazali, Haidar M , Ahmed, Fayyaz , Brighina, Filippo , Calabresi, Paolo , Casillo, Francesco , Chiang, Chia‐Chun , Coppola, Gianluca , Lorenzo, Cherubino Di , Diener, Hans‐Christoph , Geppetti, Pierangelo , Goicochea, María Teresa , Guérzoni, Simona , Hassan, Amr , Huessler, Eva‐Maria , Monteith, Teshamae , Özge, Aynur , Peres, Mário Fernando Prieto , Pozo‐Rosich, Patricia , Prudenzano, Maria Pia , Quattrocchi, Silvia, Rainero, Innocenzo , Romozzi, Marina , Schwedt, Todd J. , Tessitore, Alessandro , Wang, Shuu‐Jiun , Ashina, Messoud , Sacco, Simona

Mayo Clinic

Cephalalgia | April 25, 2025 | Volume: 45 | Issue: 4 | Pages: No page available

10.1177/03331024251321500 | PMID 40277321 Get It

We here present evidence-based guidelines for the pharmacological treatment of migraine. These guidelines, created by the Italian Society for the Study of Headache and the International Headache Society, aim to offer clear, actionable recommendations to healthcare professionals. They incorporate evidence-based recommendations from randomized controlled trials and expert-based opinions. The guidelines follow the GRADE approach for assessing the quality of evidence. The guideline development involved a systematic review of literature across multiple databases, adherence to Cochrane review methods, and a structured framework for data extraction and interpretation. Although the guidelines provide a robust foundation for migraine treatment, they also highlight gaps in current research, such as the paucity of head-to-head drug comparisons and the need for long-term outcome studies. These guidelines serve as a resource to standardize migraine treatment and promote high-quality care across different healthcare settings.
Evidence-based guidelines for the pharmacological treatment of migraine
Ornello, Raffaele , Caponnetto, Valeria , Ahmed, Fayyaz , Al‐Khazali, Haidar M. , Ashina, Sait , Baraldi, Carlo , Bellotti, Alessia, Cevoli, Sabina , Cheng, Shuli, Chiarugi, Alberto , Christensen, Rune Häckert , Chu, Min Kyung , Crema, Santiago , Stefano, Vincenzo Di , Ekizoğlu, Esme , Fallacara, Adriana , Favoni, Valentina , Garces, Kimberly, Granato, Antonio, Granella, Franco, Ha, Woo‐Seok , Hirata, Koichi , Hoffmann, Jan , Hüssler, Eva-Maria, Hussein, Mona , Jenkins, Bronwyn , Labastida‐Ramírez, Alejandro , Laporta, Anna, Levin, Morris , Lupica, Antonino , Mampreso, Edoardo, Martinelli, Daniele , Orologio, Ilaria, Panneerchelvam, Lavindren Luke, Quattrocchi, Silvia, Romanenko, V.I. , Romozzi, Marina , Russo, Antonio , Sances, Grazia , Sarchielli, Paola , Silvestro, Marcello , Tassorelli, Cristina , Tessitore, Alessandro , Christensen, Rune H. , Ashina, Sait , Baraldi, Carlo , Bellotti, Alessia , Casillo, Francesco , Chiang, Chia-Chun , Chu, Min Kyung , Coppola, Gianluca , Corbelli, Ilenia , De Icco, Roberto , de Tommaso, Marina , Di Stefano, Vincenzo , Diener, Hans-Christoph , Favoni, Valentina , Ha, Woo-Seok , Hoffmann, Jan , Hussein, Mona , Iannone, Luigi Francesco , Martinelli, Daniele , Monteith, Teshamae S , Pan, Li-Ling Hope , Rozen, Todd D. , Souza, Marcio Nattan P , Pozo-Rosich, Patricia , Rainero, Innocenzo , Romozzi, Marina , Russo, Antonio , Schwedt, Todd J , Swerts, Diego Belandrino , Tassorelli, Cristina , Togha, Mansoureh , Vaghi, Gloria , Wang, Shuu-Jiun , Ornello, Raffaele , Al-Khazali, Haidar M , Ahmed, Fayyaz , Ambrosini, Anna , Brighina, Filippo , Calabresi, Paolo , Casillo, Francesco , Chiang, Chia‐Chun , Coppola, Gianluca , Lorenzo, Cherubino Di , Diener, Hans‐Christoph , Geppetti, Pierangelo , Goicochea, María Teresa , Guérzoni, Simona , Hassan, Amr , Huessler, Eva‐Maria , Monteith, Teshamae , Özge, Aynur , Peres, Mário Fernando Prieto , Pozo‐Rosich, Patricia , Prudenzano, Maria Pia , Quattrocchi, Silvia, Rainero, Innocenzo , Romozzi, Marina , Schwedt, Todd J. , Tessitore, Alessandro , Wang, Shuu‐Jiun , Ashina, Messoud , Sacco, Simona

Mayo Clinic

Cephalalgia | April 25, 2025 | Volume: 45 | Issue: 4 | Pages: No page available

10.1177/03331024241305381 | PMID 40277319 Get It

We here present evidence-based guidelines for the pharmacological treatment of migraine. These guidelines, created by the Italian Society for the Study of Headache and the International Headache Society, aim to offer clear, actionable recommendations to healthcare professionals. They incorporate evidence-based recommendations from randomized controlled trials and expert-based opinions. The guidelines follow the Grading of Recommendations, Assessment, Development and Evaluation approach for assessing the quality of evidence. The guideline development involved a systematic review of literature across multiple databases, adherence to Cochrane review methods, and a structured framework for data extraction and interpretation. Although the guidelines provide a robust foundation for migraine treatment, they also highlight gaps in current research, such as the paucity of head-to-head drug comparisons and the need for long-term outcome studies. These guidelines serve as a resource to standardize migraine treatment and promote high-quality care across different healthcare settings.
Beyond the Echo: Is Comprehensive Vascular Exploration Valuable in Cases of Non-Syndromic Thoracic Aortic Aneurysms or Bicuspid Aortic Valve?
Saugstad, Austin , Ravi, Srekar , Bcharah, George , Bcharah, Hend , Nabi, Hussein Abdul , Pham, Hoang Nhat , Ibrahim, Ramzi, Kumar, Sant , Abdelnabi, Mahmoud , Baudhuin, Linnea M. , Wang, Yuxiang , Shamoun, Fadi , Firth, Christine E, Bcharah, Hend , Abdul Nabi, Hussein , Nhat, Hoang , Kumar, Sant J , Firth, Christine , Ibrahim, Ramzi, Osundiji, Mayowa A.

Mayo Clinic

Journal of Cardiovascular Development and Disease | April 24, 2025 | Volume: 12 | Issue: 5 | Pages: 167

10.3390/jcdd12050167 | PMID 40422938 Get It

Bicuspid aortic valve (BAV) and thoracic aortic aneurysms and dissections (TAAD) are recognized in syndromic connective tissue diseases (CTD), but most cases occur sporadically. The extent to which non-syndromic BAV or TAAD predisposes to additional arteriopathies, particularly in younger individuals, remains unclear. We retrospectively analyzed 1438 patients (mean age = 48.0, 67.7% female), excluding those with CTDs. Participants were ≤60 years old and categorized by the presence of BAV and/or TAAD. We examined co-existing arterial pathologies, including fibromuscular dysplasia, spontaneous coronary artery dissection, abdominal aortic aneurysms (AAA), mesenteric, peripheral extremity, and carotid/cerebral arteriopathies. Overall, 44.6% had either BAV or TAAD, and 27.2% had multiple arteriopathies. While vascular diseases were frequently noted, odds ratios demonstrated no significantly increased risk of extra-aortic arteriopathies in the BAV or TAAD cohorts. AAA exhibited a non-significant trend toward higher prevalence in TAAD patients. These findings support current guidelines recommending targeted imaging (transthoracic echocardiography of the aortic root and ascending aorta) over comprehensive “head-to-pelvis” screening for non-syndromic BAV or TAAD patients without additional risk factors. Ongoing genetic analyses may elucidate whether particular variants predispose to multi-site aneurysms or dissections. Consequently, targeted surveillance remains appropriate, with broader imaging reserved for patients with genetic or clinical indicators of higher risk.
Dynamic Fluid‐Assisted Continuous Multimaterial 3D Printing for Seamless Gradient Structures
Wang, Wenbo , Liu, Siying , Liu, Luyang , Nogueira, Cauê , Chen, Xiangfan , Chen, Xiangfan , Ma, Xiaoli , Xu, Xin , Shefi, Orit , Lancaster, Jessica

Mayo Clinic

Advanced Materials Technologies | April 23, 2025 | Volume: 10 | Issue: 15 | Pages: No page available

10.1002/admt.202500621 Get It

AbstractFunctionally gradient materials emulate nature's ability to seamlessly blend properties through variations in material composition, unlocking advanced engineering applications such as biomedical devices and high‐performance composites. Additive manufacturing, particularly stereolithography, enables sophisticated 3D geometries with diverse materials. However, current stereolithography‐based multi‐material 3D printing is constrained by time‐intensive material switching and compromised interfacial properties. To overcome these challenges, we present dynamic fluid‐assisted micro continuous liquid interface production (DF‐µCLIP), a high‐speed multi‐material 3D printing platform that integrates varying compositions in a fully continuous fashion. By utilizing the polymerization‐free “dead zone”, vliquid resins are seamlessly replenished within a resin bath equipped with dynamic fluidic channels and a synchronized material supply system. DF‐µCLIP achieves ultra‐fast printing speeds of 90 mm/hour with 7.4 µ m pixel‐1 resolution while enabling on‐the‐fly material transitions. This strategy enhances mechanical strength at multi‐material interface through entangled polymer networks and promotes seamless material transitions between distinct materials ilike fragile hydrogels and rigid polymers, addressing interfacial failure caused by mismatch of swelling behavior. Additionally, dynamic material replenishment with real‐time composition control enables continuous gradient printing instead of the conventional step‐wise controlled gradient. Demonstrations include polymers with gradient color transitions and gradient carbon nanotube (CNT) composites with seamlessly varying conductivity.